Carboplatin plus paclitaxel in combination with bevacizumab for the treatment of adenocarcinoma with interstitial lung diseases

Suzuki,Hidekazu; Hirashima,Tomonori; Kobayashi,Masashi; Okamoto,Norio; Matsuura,Yuka; Tamiya,Motohiro; Morishita,Naoko; Okafuji,Kohei; Shiroyama,Takayuki; Morimura,Osamu; Morita,Satomu; Kawase,Ichiro

doi:10.3892/mco.2013.82

Carboplatin plus paclitaxel in combination with bevacizumab for the treatment of adenocarcinoma with interstitial lung diseases

Authors:
- Hidekazu Suzuki
- Tomonori Hirashima
- Masashi Kobayashi
- Norio Okamoto
- Yuka Matsuura
- Motohiro Tamiya
- Naoko Morishita
- Kohei Okafuji
- Takayuki Shiroyama
- Osamu Morimura
- Satomu Morita
- Ichiro Kawase
View Affiliations

Affiliations: Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka 583-8588, Japan
Published online on: March 1, 2013 https://doi.org/10.3892/mco.2013.82
Pages: 480-482

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Interstitial lung diseases (ILDs) are frequently associated with lung cancer. The safety of carboplatin plus paclitaxel in combination with bevacizumab (CP-B) in patients with ILD and lung cancer (ILD-LC) remains to be clarified. In the present study, the safety and efficacy of CP-B treatment in ILD-LC patients were retrospectively investigated. Four patients, who completed CP-B therapy, were included in this study. The dose of carboplatin was the area under the curve 5, paclitaxel was 200 mg/m2 and bevacizumab was 15 mg/kg at treatment initiation. The patients were males, had histologically confirmed adenocarcinoma, were smokers and demonstrated non-usual interstitial pneumonia (non‑UIP) patterns on computed tomography (CT). Patients received 1-6 cycles of CP-B therapy. Three of the four patients received maintenance bevacizumab therapy for 3-10 cycles. Only one patient demonstrated a partial response. Neutropenia was the most frequent adverse event. One patient experienced gut perforation during the first course of CP-B. No pulmonary toxicity was observed. Thus, treatment of ILD-LC patients with CP-B was not associated with pulmonary toxicity, however, this study population appeared to be at a low risk.

View Figures

View References

1.	Bouros D, Hatzakis K, Labrakis H and Zeibecoglou K: Association of malignancy with diseases causing interstitial pulmonary changes. Chest. 121:1278–1289. 2002. View Article : Google Scholar : PubMed/NCBI
2.	Isobe K, Hata Y, Sakamoto S, Takai Y, Shibuya K and Homma S: Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anticancer therapy. Respirology. 15:88–92. 2010. View Article : Google Scholar
3.	Minegishi Y, Sudoh J, Kuribayasi H, Mizutani H, Seike M, Azuma A, Yoshimura A, Kudoh S and Gemma A: The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer. 71:70–74. 2011. View Article : Google Scholar : PubMed/NCBI
4.	Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar
6.	Chugai Pharmaceutical Co, Ltd.: http://chugai-pharm.jp/hc/ss/pr/safe/report/ava/index.html. Accessed July 26, 2012.
7.	Usui K, Katou Y, Furushima K, Tanaka Y, Tanai C and Ishihara T: Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients. Jpn J Clin Oncol. 41:498–502. 2011. View Article : Google Scholar : PubMed/NCBI
8.	Tamura J, Nakauchi M, Nakayama Y, Kitaguchi K, Sakikubo M, Ura K, Taira K, Ohe H, Yoshikawa A, Ishigami S and Baba N: A case of interstitial pneumonitis induced by FOLFIRI+bevacizumab combination therapy for liver and lung metastasis of colon cancer. Gan To Kagaku Ryoho. 36:2665–2668. 2009.(In Japanese).
9.	Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K, Matsui K, Negoro S, Yokoyama A, Kudoh S, Kiura K, Mori K, Okamoto H, Sakai H, Takeda K, Yokota S, Saijo N and Fukuoka M; JO19907 Study Group: Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 76:362–367. 2012. View Article : Google Scholar : PubMed/NCBI
10.	Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Kluglich M and du Bois RM: Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 365:1079–1087. 2011. View Article : Google Scholar : PubMed/NCBI
11.	Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, Stopfer P and von Pawel J: A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small cell lung cancer. Ann Oncol. 22:1374–1381. 2011. View Article : Google Scholar : PubMed/NCBI
12.	US National Institutes of Health: Lume-Lung 1: BIBF 1120 plus docetaxel as compared to placebo plus docetaxel in 2nd line non-small cell lung cancer. http://clinicaltrials.gov/ct2/show/NCT00805194. Accessed July 26, 2012.
13.	US National Institutes of Health: Lume-Lung 2: BIBF 1120 plus pemetrexed compared to placebo plus pemetrexed in 2nd line nonsquamous NSCLC. http://clinicaltrials.gov/ct2/show/NCT00806819. Accessed July 26, 2012.